Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics, discussed key factors associated with poor behavioral health issues and quality of life among patients with psoriasis.
Severity, location, and symptom burden of psoriasis are 3 key factors associated with risk of adverse behavioral health and quality of life issues in patients, said Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics.
Transcript
Can you discuss risk factors for adverse behavioral outcomes in patients with psoriasis?
I think the extent of the disease that a patient has is really important in that, as well as the location, and then their symptoms. So, if we think about those 3 factors, the extent of disease—obviously if a patient only has the typical plaque psoriasis locations and it's a very low percentage of their overall body surface area (BSA) or maybe it's in an area that is easily hidden from public viewing during their regular week, then the impact of that on their quality of life may be somewhat less. We certainly see a correlation between that and more severe disease, and severe disease usually means higher BSA. And so that's one aspect that I think is important.
The other one is the location. So, we talked about intertriginous psoriasis as a key location. Obviously, and even in our Harris Poll data, we found out that intertriginous disease has a big impact on those intimate aspects of a patient's life. So, sexual function, comfort with engaging in sexual activity—those are impacted by a patient having intertriginous psoriasis, because although it may not be visible to people in your daily life, in those moments, it becomes very important to you. And that's an important aspect of life and something that oftentimes patients might not be talking about.
And then the third aspect, I would say, is really the symptoms. So, if a patient is very symptomatic, and the number one symptom is itch in psoriasis, then that's going to have an impact on their quality of life and can kind of repeatedly disrupt their normal activities throughout the day because they're focusing more so on their psoriasis than on what they're meant to be paying attention to in their work or in caring for their family or whatever it is that they spend their day doing.
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
SGLT2 Inhibitors Show Renal Benefits in HF and CKD as Prescribers Target Uptake Gaps
April 15th 2025Abstracts featured at the National Kidney Foundation Spring Clinical Meeting highlighted the renoprotective benefits of SGLT2 inhibitors in heart failure and diabetic kidney disease while emphasizing the need for strategies to increase their uptake in primary care.
Read More